Project Grant R01AI184394
Award Date 8/12/25
Completion Date 5/31/29
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award of $269,874 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis (MTB) vaccine, by Solaris Vaccines, Inc. The goal is to create a scalable and cost-effective vaccine that triggers both systemic and pulmonary immunity to improve protection against tuberculosis (TB), which kills...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,640,492 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine to study the role of the ESX5 secretome of Mycobacterium tuberculosis in TB and TB-HIV pathogenesis and immunity. The researchers generated a genetic deletion of the ESX5 locus, which they found produced a live attenuated vaccine that is highly effective at preventing TB in...
- This Project Grant award, valued at $2,324,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose is to optimize an oral BCG (Bacille Calmette-Guerin) vaccination regimen against tuberculosis (TB), a leading cause of infectious death worldwide. The research aims to: 1) Optimize the oral BCG regimen, 2) Compare the efficacy of oral BCG to intravenous and intradermal BCG in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is providing $905,998 to the Texas Biomedical Research Institute (TxBiomed) to evaluate the safety, immunogenicity, and efficacy of a novel attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the context of HIV co-infection. The research aims to understand whether this live-replicating MTB vaccine can...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,166,933 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center to study Mycobacterium tuberculosis transmission. The project aims to identify bacterial genetic and phenotypic features associated with M. tuberculosis transmission outcomes, including infection, subclinical TB, and clinical TB disease. It will also define M. tuberculosis...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This federal Project Grant award for $711,993.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to examine the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis in people living with HIV (PWH). The research aims to assess how MTB disease influences the development of broadly neutralizing HIV-1 antibodies, the emergence of NAb-resistant viral...